Kynexis is a burgeoning startup founded in 2023, operating at the intersection of Biotechnology and Health Care. The company is leading a biomarker-driven approach to therapeutics, focusing on brain diseases. Its mission, captured succinctly in its slogan—“Kynexis is advancing the first potential precision medicine for the treatment of CIAS.”—speaks to its innovative vision.
The company is dedicated to developing precision medicine solutions, with a keen focus on KAT-II, a pivotal enzyme in the kynurenine pathway. Their lead candidate, KYN-5356, is a first-in-class, highly selective small molecule aimed at treating cognitive impairment associated with schizophrenia (CIAS).
In the world of investment, Kynexis recently secured a substantial €57.00M Series A investment round dated 01 November 2023. This robust support includes esteemed investors such as Forbion, Ysios Capital, and Sunstone Life Science Ventures, underscoring strong confidence in the company's potential to revolutionize treatment in its niche market.
